IDRx

IDRx is a biopharmaceutical company developing precision combination therapies for cancer treatment. The company aims to address the limitations of current precision cancer medicines by creating highly selective drug combinations that target key tumor escape mechanisms. 

The company's lead product candidate, IDRX-42, is an oral selective KIT inhibitor acquired from Merck KGaA, designed to target all major categories of activating and resistance mutations in patients with KIT-mutant gastrointestinal stromal tumors (GIST). As of June 2024, IDRX-42 was being evaluated in the Phase 1/1b StrateGIST 1 study for patients with metastatic and/or unresectable GIST who had previously received one or more prior lines of tyrosine kinase inhibitor therapy.

In November 2023, IDRx presented preliminary clinical data from the StrateGIST 1 study at the Connective Tissue Oncology Society (CTOS) Annual Meeting. The data reportedly showed anti-tumor activity and a favorable safety profile for IDRX-42 in heavily pre-treated GIST patients, with the objective response rate being 23% across all 28 evaluable patients and 43% in second-line patients.

IDRx's pipeline also includes IDRX-73, another small molecule tyrosine kinase inhibitor acquired from Blueprint Medicines, designed to inhibit key genetic drivers and drug-resistant mutations of GIST. As of 2024, IDRX-42 had Orphan Drug Designation by the US FDA for the treatment of GIST.

Key customers and partnerships

The company entered a licensing agreement with Merck KGaA, Darmstadt, Germany, to obtain IDRX-42 in 2022. In the same year, IDRx also acquired IDRX-73 through a licensing agreement with Blueprint Medicines.